

Return on Innovation



Global health R&D delivers for Alabama



US government (USG) investment in global health R&D has delivered

\$68.7 million
to Alabama research institutions*

850+ new jobs
for Alabama†

Alabama's top global health R&D institutions by USG funding*

| ORGANIZATION | FUNDING |
|-------------------------------------|----------------|
| University of Alabama at Birmingham | \$53.3 million |
| Southern Research Institute | \$14.1 million |
| Auburn University | \$876 thousand |
| Alabama State University | \$341 thousand |


Neglected diseases in Alabama‡

| | |
|--------------------|-------|
| HIV diagnoses | 5,943 |
| Tuberculosis cases | 1,257 |
| West Nile cases | 127 |
| Malaria cases | 66 |
| Zika cases | 40 |

Alabama industry in global health R&D


CNine Biosolutions: Birmingham
Biocryst Pharmaceuticals: Birmingham

Global health R&D at work in the Heart of Dixie



The University of Alabama at Birmingham School of Medicine operates the Antiviral Drug Discovery and Development Center (AD3C), funded by the US National Institutes of Health. AD3C focuses on developing drug therapies for diseases such as influenza, West Nile virus, SARS, chikungunya, and dengue. Researchers work to target and inhibit enzymes essential for viral replication. The viruses AD3C targets are of high priority for the US government as the global burden of these diseases is enormous, with West Nile virus and influenza routinely infecting US citizens. Southern Research Institute in Birmingham is supporting AD3C in screening potential compounds.

Alabama's top areas of global health R&D by USG funding*



GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES§

89¢ of every dollar
the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

200K new US jobs

\$33 BILLION in US economic growth.

*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghtcoalition.org for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See www.ghtcoalition.org for additional details.
‡Centers for Disease Control and Prevention: HIV diagnoses 2008–2016, Tuberculosis cases 2008–2016, West Nile virus disease cases 2008–2016, Malaria cases 2008–2014, Zika virus disease cases 2015–2017.

§Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

¶NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.